Your Messages Inbox
Your Article Summary
See Latest ArticlesForest Laboratories and AstraZeneca to Co-Develop and Commercialize a Late Stage Next Generation Anti-Infective
Forest Laboratories, 08/13/09
Forest Laboratories and AstraZeneca announced they have entered into a definitive collaboration agreement to co–develop and commercialize ceftaroline in all markets outside the United States, Canada and Japan. Ceftaroline is Forest's late stage, next generation cephalosporin being investigated for the treatment of complicated skin and skin structure infections and community–acquired bacterial pneumonia. Ceftaroline demonstrates bactericidal activity against a broad range of pathogens commonly implicated in cSSSI and CABP, including methicillin–resistant Staphylococcus aureus and multi–drug resistant Streptococcus pneumoniae.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09
Harris Corp. Buys VA Contractor
HealthDataManagement, 11/23/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
Shire, 11/30/09
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09
Article Search
Sponsor